Reviva Pharmaceuticals Holdings Inc.

NASDAQ:RVPH   3:59:32 PM EDT
0.82
+0.11 (+15.51%)
Products, Regulatory

Reviva Pharmaceuticals Provides Update On Clinical Development Pipeline

Published: 07/27/2022 11:30 GMT
Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline.
Reviva Pharmaceuticals Holdings, Inc. - Anticipates Initiating Two Phase 2a Trials Targeting Adhd and Pulmonary Arterial Hypertension in Q4 2022.
Reviva Pharmaceuticals - Enrollment Remains on Pace for Reviva's Phase 3 Clinical Trial for Treatment of Schizophrenia at 15 Sites Across Us.
Reviva Pharmaceuticals - Enrollment for Phase 3 Clinical Trial for Treatment of Schizophrenia Set to Begin at Sites in Europe and India in Q3 2022.
Reviva Pharmaceuticals Holdings, Inc. - Top-line Data From Recover Trial is Expected in Mid-2023.